WASHINGTON, D.C. — Medicare beneficiaries could soon gain significantly cheaper access to certain weight-loss and diabetes-related medications under a new federal demonstration program that will cap some monthly GLP-1 prescription costs at $50 beginning July 1, 2026. What This Means for You
Eligible Medicare Part D beneficiaries may pay $50 per month for certain GLP-1 medications starting July 1, 2026. The temporary federal demonstration progra…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.